文献速递前列腺癌

基于风险选择前列腺穿刺活检的额外获益:欧洲前列腺癌筛查随机研究鹿特丹部分活检并发症分析

Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
PubMed 文献 · BJU Int · 2017-06-05

该研究纳入欧洲前列腺癌筛查随机研究(ERSPC)鹿特丹部分1993至2015年间10747例次完整问卷的活检,并发症率67.9%,发热率3.9%,入院率0.9%,入院率从0.6%(1993-1996)升至2.1%(2009-2015);在符合风险计算器标准的7704例次活检中,使用ERSPC风险计算器可避免35.8%的活检、37.4%的并发症、39.4%的发热事件和42.3%的入院,并节省35.9%的总费用。

要点

  • 活检并发症率67.9%,发热率3.9%,入院率0.9%,入院率从0.6%(1993-1996)升至2.1%(2009-2015)。
  • 符合风险计算器标准的7704例次活检中,可避免35.8%的活检、37.4%的并发症和42.3%的入院。
  • 使用ERSPC风险计算器可避免35.9%的活检及并发症治疗总费用。

核心结论

  • 若活检决策基于ERSPC风险计算器而非仅基于PSA,可显著减少相当比例的活检并发症、入院和费用,该效应在近年活检及重复活检或筛查男性中最为突出。

研究设计与样本

  • 纳入ERSPC鹿特丹部分1993至2015年间所有活检,并发症和入院数据通过活检后2周完成的问卷前瞻性记录,共10747例次完整问卷活检。
  • 对首次和后续筛查轮次男性分别应用ERSPC风险计算器3(RC3)和4(RC4),采用预设前列腺癌风险≥12.5%和高危前列腺癌风险≥3%的阈值评估可避免的并发症、入院和费用。

主要发现

  • 10747例次活检中,并发症率67.9%(7294/10747),活检后发热率3.9%(424/10747),入院率0.9%(92/10747)。
  • 发热率历年保持稳定,但入院率从0.6%(1993-1996)增至2.1%(2009-2015),增至约三倍。
  • 符合RC3或RC4标准的7704例次活检中,可避免35.8%的活检(2757/7704)、37.4%的并发症(1972/5268)、39.4%的发热事件(128/325)和42.3%的入院(30/71)。
  • 使用RC4及针对近年(2009-2015)活检时可避免更多并发症。
  • 可避免活检及并发症治疗总费用的35.9%。

关键数值与推荐

  • RC3/RC4预设前列腺癌风险阈值≥12.5%,高危前列腺癌风险阈值≥3%。

临床怎么用

  • 作者认为,活检决策基于ERSPC风险计算器而非仅基于PSA可减少活检并发症、入院和费用,该效应在近年活检及重复活检或筛查男性中最为突出。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate biopsy complications and hospital admissions that could be reduced by the use of European Randomized Study of Screening for Prostate Cancer (ERSPC) risk calculators. MATERIALS AND METHODS: All biopsies performed in the Rotterdam section of the ERSPC between 1993 and 2015 were included. Biopsy complications and hospital admission data were prospectively recorded in questionnaires that were completed 2 weeks after biopsy. The ERSPC risk calculators 3 (RC3) and 4 (RC4) were applied to men attending the first and subsequent rounds of screening, respectively. Applying the predefined RC3/4 probability thresholds for prostate cancer (PCa) risk of ≥12.5% and high-grade PCa risk ≥3%, we assessed the number of complications, admissions and costs that could be reduced by avoiding biopsies in men below these thresholds. RESULTS: A total of 10 747 biopsies with complete questionnaires were included. For these biopsies a complication rate of 67.9% (7294/10 747), a post-biopsy fever rate of 3.9% (424/10747) and a hospital admission rate of 0.9% (92/10747) were recorded. The fever rate was found to be static over the years, but the hospital admission rate tripled from 0.6% (1993-1996) to 2.1% (2009-2015). Among 7704 biopsies which fit the criteria for RC3 or RC4, 35.8% of biopsies (2757/7704), 37.4% of complications (1972/5268), 39.4% of fever events (128/325) and 42.3% of admissions (30/71) could have been avoided by using one of the risk calculators. More complications could have been avoided if RC4 had been used and for more recent biopsies (2009-2015). Our findings show that 35.9% of the total cost of biopsies and complication treatment could have been avoided. CONCLUSION: A significant proportion of biopsy complications, hospital admissions and costs could be reduced if biopsy decisions were based on ERSPC risk calculators instead of PSA only. This effect was most prominent in more recent biopsies and in men with repeated biopsies or screening.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Chiu PK, Alberts AR, Venderbos LDF, et al. Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. BJU Int. 2017. PMID: 28498624. doi:10.1111/bju.13913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。